Navigation Links
Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
Date:3/27/2008

RANCHO MIRAGE, Calif., March 27 /PRNewswire/ -- In the medical community at large, there is no disputing the fact that heart attacks kill and destroy cells in the heart muscle. Multiple attempts by medical research scientists to figure out how to stimulate the heart to repair itself after an individual suffers a heart attack have repeatedly failed ... until now!

The Weil Institute of Critical Care Medicine, located in Rancho Mirage, California, is home to a brilliant group of medical research scientists who strive on a daily basis to provide cutting-edge breakthroughs to improve the success of preserving the life of those that suffer sudden cardiac arrest. This dynamic team, headed by world-renowned heart surgeon Dr. Wanchung Tang, sought to find the answer to rejuvenate the cells that were damaged and destroyed in the heart muscle from a heart attack. The beginning of this brilliant discovery started with the theory that by using bone marrow, the stem cells in the marrow would find their way to the heart muscle and begin to take over the function of the damaged and destroyed cells. These stem cells, in effect, would replace the dead cells and adapt themselves to become viable beating heart cells!

The Weil Institute medical investigation team has published its findings in various medical journals around the world. They have successfully been able to produce new, fully functional heart cells using the bone marrow donated from rats. The stem cells, once injected into the blood stream over a period of time, did indeed find their way to the heart and replaced the damaged cells that had been destroyed. Most importantly, these are the cells that had been destroyed due to a heart attack. New cells were effectively created and after painstaking monitoring over a period of time, it was duly found that the heart function of the subject improved significantly. To find out how you can become involved with The Weil Institute of Critical Care Medicine and par
'/>"/>

SOURCE Weil Institute of Critical Care Medicine
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
2. Velos to Develop Key System Interface for Clinical Research
3. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
4. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
5. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
9. Women Invited to Join New Health Registry to Advance Research
10. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
11. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ROCKVILLE, Md., Nov. 9 OriGene Tec... Technology in Sweden has adopted its VERIFY Tagge...an Protein Atlas program. This program is funded b...set up to explore the human proteome systematicall...h quality mono-specific antibodies in a high throu...
(Date:11/9/2009)...ST. LOUIS, Nov. 9, 2009 ...E: PFE ) today announced that they have entered i...Chesterfield Village Research Center located in Ch... Monsanto will acquire the property from Pfizer fo...ll continue to have operations at Chesterfield Vil...
(Date:11/9/2009)...VIRGINIA BEACH, Va., Nov. 9 LifeNe... announces the launch of Vertigraft Cervical Bio-I..., Preservon® is a new, proprietary glycerol-b...io-implants to be stored in a fully hydrated state...to freeze or freeze-dry bio-implants, doing away w...
Breaking Medicine Technology:Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3LifeNet Health Announces First Bio-Implant with New Preservation Technology 2Gene Therapy Shows Promise for Parkinsons 59471 1Gene Therapy Shows Promise for Parkinsons 59471 2Gene Therapy Shows Promise for Parkinsons 59471 3Experts Summarize State of the Science in Autism Disorders 59468 1Experts Summarize State of the Science in Autism Disorders 59468 2Experts Summarize State of the Science in Autism Disorders 59468 3Experts Summarize State of the Science in Autism Disorders 59468 4Jack LaLanne Celebrated as Fitness Icon at Star Studded Birthday Bash 59465 1Jack LaLanne Celebrated as Fitness Icon at Star Studded Birthday Bash 59465 2
...antly Reduced Signs of Disease Activity as Measure..., 2007 -- Genentech, Inc.,(NYSE: DNA) and Biogen... data from a Phase II clinical study of Rituxan&re...g multiple sclerosis,(RRMS) were presented today a... held in Boston. Rituxan is a therapeutic antibody...
...tzerland, May 2, 2007 – Merck,Serono S.A. (v...,safinamide, a new agent in Phase III development ...ptoms, were presented by Professor,Fabrizio Stocch...,Meeting in Boston, Massachusetts, USA. These data... blind, placebo-controlled,international trial. ,...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 2Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 3Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 4Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 5
(Date:11/9/2009)... 9 Speaker Nancy Pelos...ions in the Affordable Health Care for America ...aid and reduce Medicare Part D costs for people li...Saturday by a vote of 220 to 215: ,, "Effectiv...ality of life for thousands of Americans living wi...
(Date:11/9/2009)...e, Nov. 9 At a time when the 250,0...easingly concerned about finding affordable health...ption for 2010. ,, The Today,s Options® Pr...tage plan provides a cost-effective and comprehens... Supplement plan. People with Medicare can choose...
(Date:11/9/2009)... 9 The American Academy... than 75,000 clinically practicing physician assis...uds the U.S. House of Representatives for passing ...he Affordable Health Care for America Act. ,, "...will ultimately lower the cost of health care and ...
(Date:11/9/2009)...Research Hospital and the University of Florida Pr... to provide proton therapy for St. Jude patients. ... clinical study to evaluate the use of proton ther...n 3 years old. , Under the clinical protocol, ...rapy at the UF Proton Therapy Institute in Jackson...
(Date:11/9/2009)...er 9, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), t...ay announced the availability of INTUNIV (guanfaci...the United States for the treatment of Attention-D...nd adolescents ages 6 to 17. INTUNIV, a once-dail... nonscheduled alpha-2A receptor agonist approved f...
Breaking Medicine News(10 mins):Health News:Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS 2Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4
...ustralians face increasingly large-scale,health ri...onment, ranging from,increases in weather extremes...health., Twelve of Australias top health and medic...ustralians., Released today by Research Australia,...
...research tracks the spread of HIV from Africa to A...s) -- New research into the genetic history of HIV...in Haiti during the middle of the last century, pr... into how HIV evolves and moves from place to plac...
...N, Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: ...he third quarter,and nine-months ended September 3... Clinical:, -- Patient enrollment began in a Pha...stem cell transplant patients; study enrollment ex...
...es Fiscal Year EPS Outlook for One-time Tax Benefi...e Company (NYSE: PG ) announced net sales growth ... Every reportable segment delivered,mid-single dig... Fabric & Home Care, Baby & Family Care and Groomi...
...CETON, N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX... at the,JPMorgan Small/Mid Cap Conference in Bosto...Time. Medarex,s presentation will be webcast live ...arex.com . About Medarex Medarex is a biopharmac...
...JOSEPH, Mich., Oct. 30 GeneGo, Inc., the leading,...t Elan Pharmaceuticals,Inc. licensed its flagship ...l be available to all scientists in research. Meta... very pleased that Elan chose GeneGo and we have h...
Other Medicine News:Health News:Healthy planet, places and people at risk 2Health News:AIDS Stopped in Haiti Before U.S. 2Health News:AIDS Stopped in Haiti Before U.S. 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 2Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 3Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 4Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 5Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 6Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 7Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 8Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 9Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 11Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 12Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 13Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 14Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 15Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 16
Light Guide Cables - 2.0mm
3mm Universal Light Guide
Fiberoptic Light Guide with Fixed ACMI™ Light Source End
Fiberoptic Light Guide, clip-on
Medicine Products: